EVAOLD trial: Routine invasive strategy reaffirmed for older heart attack patients
A major question in cardiology is how aggressively to treat very old patients who suffer a common type of heart attack. New research presented today at ESC Congress 2026 provides a clear answer: one of the oldest patients should still receive routine invasive care, rather than a more selective approach guided by stress imaging. The EVAOLD trial, which was stopped early for futility, strengthens the evidence that routine coronary angiography and appropriate revascularization should remain the standard of care in this population.
The trial, led by Professor Gilles Barone-Rochette of University Hospital of Grenoble in France, was designed to test whether a noninvasive stress test could help choose which elderly patients with non-ST-elevation myocardial infarction (NSTEMI) would benefit from an invasive strategy. The researchers hypothesized that a stress-imaging-first approach might prevent unnecessary procedures in older adults, who are at higher risk of complications. However, at a planned interim analysis, this selective strategy was not shown to be as safe or effective as the traditional approach, leading the data safety monitoring board to halt enrollment.
Understanding NSTEMI, the most common heart attack
NSTEMI is a subset of acute coronary syndrome in which a partial blockage of a coronary artery reduces blood flow to the heart muscle. It is characterized by an elevation in cardiac biomarkers but, unlike the more well-known ST-elevation myocardial infarction (STEMI), it does not produce the classic pattern on an electrocardiogram. NSTEMI can still cause significant damage to the heart and is associated with a substantial long-term risk of death or recurrent events. Because it occurs more often in older adults, treatment decisions in this age group carry particularly high stakes.
Standard management of NSTEMI in many guidelines includes an early invasive strategy: patients undergo coronary angiography, during which a thin catheter is used to inject contrast dye into the coronary arteries, allowing doctors to identify and, if necessary, open narrowed or blocked vessels with balloon angioplasty and stents. This approach is supported by decades of data in younger and middle-aged patients, but its benefits in the elderly have remained less certain.
The particular challenge in older patients
Adults aged 80 and older often have complex medical histories, including hypertension, diabetes, kidney disease, and peripheral vascular disease. Their hearts may be frailer, and their vascular systems more tortuous or calcified, which can increase the risks of invasive procedures. Additionally, older patients frequently take multiple medications, and the risks of bleeding from antiplatelet and anticoagulant therapies are higher. These factors make any decision to undergo angiography and possible revascularization more difficult.
“The benefit-risk balance of routine invasive management remains uncertain in older patients due to the increased risk of complications and the lack of evidence of its benefit from randomized trials,” Barone-Rochette and colleagues noted at the start of the study. Many cardiologists therefore practice a more selective approach, reserving invasive treatment for those with evidence of ongoing ischemia or severe disease on noninvasive testing.
Stress imaging as a ‘gatekeeper’
The idea behind the EVAOLD trial was that a noninvasive stress test could act as a gatekeeper, identifying which older patients would truly benefit from an invasive strategy. Stress testing is widely used in cardiology to detect ischemic heart disease. The test involves administering a medication that makes the heart work harder for a brief period while imaging the heart using echocardiography or single-photon emission computed tomography (SPECT). By observing how the heart muscle contracts and receives blood under stress, doctors can identify areas of reversible ischemia, which might suggest a critically narrowed coronary artery.
In EVAOLD, patients randomly assigned to the selective strategy first underwent stress imaging. Only those showing moderate to severe ischemia were then sent for angiography. The majority of older patients, who often have less extensive disease or a higher burden of other health problems, might have been spared the risks of an unnecessary invasive procedure. But the trial did not confirm this theory.
Trial design and patient population
EVAOLD was an open-label, multicenter, randomized trial conducted at 25 centers in France. It recruited patients aged 80 or older who had been hospitalized with NSTEMI. Participants were assigned to either:
- A routine invasive strategy, in which all patients underwent coronary angiography without prior stress testing, followed by appropriate revascularization if blockages were found.
- A stress-imaging-guided selective invasive strategy, in which patients first had a stress test and only those with moderate or severe ischemia were referred for angiography.
The primary endpoint was designed to capture major clinical consequences: death from any cause and nonfatal myocardial infarction. The research team planned to enroll 1,756 patients to have sufficient statistical power to confirm that the selective approach was not worse (noninferior) than routine invasive management, within a prespecified margin.
Stopped early for futility
At the first prespecified interim analysis, the trial had randomized 587 patients. The independent data monitoring committee reviewed the results and recommended stopping the study immediately for futility. The reason was that the conditional probability of demonstrating noninferiority, if the trial continued to its planned sample size, was very low. In other words, there was no realistic chance that the selective stress-guided strategy would turn out to be “as good as” routine invasive care. The committee therefore acted early to avoid exposing more patients to a potentially worse strategy.
Although the full results have not yet been released in detail, the decision to stop for futility sends a strong message. It suggests that the stress-imaging-first approach is unlikely to be a safe substitution for the standard invasive pathway in this vulnerable population.
Implications for clinical practice
For clinicians caring for older NSTEMI patients, the EVAOLD findings offer practical guidance. Rather than deferring or omitting invasive care in patients aged 80 and above, the trial reinforces that routine coronary angiography and revascularization should continue to be considered. The evidence does not support the widespread use of stress imaging as a gatekeeper before deciding on an invasive strategy in this age group.
“The main finding of the trial is clear: a routine invasive approach should not be replaced with a more selective approach in older patients with the most common type of heart attack,” said Barone-Rochette. The investigators stress that age alone should not disqualify a patient from guideline-directed therapy, and that decisions should be individualized, taking into consideration the patient’s overall health status and preferences.
It is important to note that a futility stop does not necessarily mean the two strategies had worse outcomes in the interim data. It does mean that the trial was unable to rule out a meaningful disadvantage of the selective strategy, and that the reassuring evidence needed to change practice was not obtained. Such findings often lead the medical community to stick with existing guidelines.
Context within acute coronary syndrome care
The release of these findings comes as the medical community continues to debate the optimal management of NSTEMI in the oldest segment of the population. Several prior observational studies had yielded conflicting results, with some suggesting older patients may not benefit as much from routine invasive care. Randomized data have historically been sparse, because trials have often excluded very old patients or enrolled too few of them. EVAOLD was specifically designed to address this gap.
The European Society of Cardiology (ESC) holds its annual congress in 2026, and the EVAOLD trial was selected for a Hot Line session, which highlights late-breaking clinical research considered likely to change practice. In that context, the failure of the selective strategy is an important negative result that helps to clarify the risk-benefit calculus.
Next steps and research directions
While EVAOLD did not complete its intended enrollment, its early stopping provides useful biological and clinical information. Future research may focus on how to reduce procedure-related complications in older patients rather than on avoiding invasive care altogether. For example, newer imaging techniques, anticoagulation protocols, or revascularization methods could lower the threshold for intervention.
Additionally, researchers may explore other clinical phenotypes, such as frailty assessments, to better tailor the use of invasive care. But the EVAOLD trial’s message is direct: a blanket policy of stress-testing all older NSTEMI patients before deciding about angiography cannot currently be recommended. As clinicians continue to balance urgency and risk in elderly patients, these data offer a measure of clarity in an area where guesses and intuition have often had to substitute for solid evidence.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
